Effective Treatment of Glioblastoma Multiforme With Oncolytic Virotherapy: A Case-Series

被引：27

作者：

Gesundheit, Benjamin ^{[1
]}

Ben-David, Eliel ^{[2
]}

Posen, Yehudit ^{[1
]}

Ellis, Ronald ^{[1
]}

Wollmann, Guido ^{[3
,4
]}

Schneider, E. Marion ^{[5
]}

Aigner, Karl ^{[6
]}

Brauns, Lars ^{[7
]}

Nesselhut, Thomas ^{[8
]}

Ackva, Ingrid ^{[9
]}

Weisslein, Christine ^{[9
]}

Thaller, Arno ^{[9
]}

机构：

[1] Rapo Yerape Ltd, Jerusalem, Israel

[2] Shaare Zedek Med Ctr, Dept Radiol, Jerusalem, Israel

[3] Med Univ Innsbruck, Inst Virol, Innsbruck, Austria

[4] Christian Doppler Lab Viral Immunotherapy Canc, Innsbruck, Austria

[5] Univ Hosp Ulm, Div Expt Anesthesiol, Ulm, Germany

[6] Medias Klin, Burghausen, Germany

[7] Arztpraxis Regerplatz, Munich, Germany

[8] Inst Tumor Therapie, Duderstadt, Germany

[9] Praxisklin Allgemeinmed, Markt Berolzheim, Germany

来源：

FRONTIERS IN ONCOLOGY | 2020年 / 10卷

关键词：

glioblastoma; immunotherapy; oncolytic virotherapy; biological therapy; Newcastle disease virus (NDV); VIRUS; THERAPY; IMMUNOTHERAPY; COMBINATION; CELLS;

D O I：

10.3389/fonc.2020.00702

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Glioblastoma multiforme (GBM) remains an incurable condition, associated with a median survival time of 15 months with best standard of care and 5-year survival rate of <10%. We report on four GBM patients on combination treatment regimens that included oncolytic virus (OV) immunotherapy, who achieved clinical and radiological responses with long-term survival, thus far, of up to 14 years, and good quality of life. We discuss the radiological findings that provide new insights into this treatment, the scientific rationale of this innovative and promising therapy, and considerations for future research.

引用

页数：6

共 50 条

[1] Current Status and Challenges of Oncolytic Virotherapy for the Treatment of Glioblastoma
Webb, Mason J.
Sener, Ugur
Vile, Richard G.
[J]. PHARMACEUTICALS, 2023, 16 (06)
[2] Oncolytic virotherapy of glioblastoma: an overview
Rommelaere, Jean
[J]. HUMAN GENE THERAPY, 2011, 22 (06) : A7 - A7
[3] Cancer stem cell plasticity in glioblastoma multiforme: a perspective on future directions in oncolytic virotherapy
Kim, David S.
[J]. FUTURE ONCOLOGY, 2020, 16 (28) : 2251 - 2264
[4] Oncolytic virotherapy safe and effective
Richards, Dan
[J]. FUTURE VIROLOGY, 2006, 1 (05) : 539 - 539
[5] CASE SERIES OF PEDIATRIC GLIOBLASTOMA MULTIFORME
Johnston, Donna
Yacob, Marina
[J]. PEDIATRIC BLOOD & CANCER, 2015, 62 : 84 - 84
[6] Glioblastoma microenvironment and its reprogramming by oncolytic virotherapy
Qi, Zhongbing
Long, Xiangyu
Liu, Jiyan
Cheng, Ping
[J]. FRONTIERS IN CELLULAR NEUROSCIENCE, 2022, 16
[7] Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy?
Stepanenko, Aleksei A.
Chekhonin, Vladimir P.
[J]. CANCERS, 2018, 10 (12)
[8] Personalizing Oncolytic Virotherapy for Glioblastoma: In Search of Biomarkers for Response
Stavrakaki, Eftychia
Dirven, Clemens M. F.
Lamfers, Martine L. M.
[J]. CANCERS, 2021, 13 (04) : 1 - 22
[9] Neurotropic Influenza A Virus as an Oncolytic Virotherapy for Glioblastoma and Melanoma
Klonoski, Joshua
Contreras, NIco
Snook, Jeremy
Palmer, Cheryl
Davidson, Christian
VanBrocklin, Matthew
Williams, Matthew
[J]. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2021, 80 (06): : 571 - 571
[10] Oncolytic myxoma virus synergizes with standard of care for treatment of glioblastoma multiforme
Burton, Chase
Das, Arabinda
McDonald, Daniel
Vandergrift, William A., III
Patel, Sunil J.
Cachia, David
Bartee, Eric
[J]. ONCOLYTIC VIROTHERAPY, 2018, 7 : 107 - 116

← 1 2 3 4 5 →